Martin G. Pomper

Oct 19, 2024 | urotoday.com | Martin G. Pomper

Read the Full Video TranscriptOliver Sartor: Hi, Dr. Oliver Sartor here with Uro Today. Very special guest, Dr. Martin Pomper. I think Dr. Pomper is well known to the field. He's been thinking about the concept of Theranostics for four decades, which is a little bit crazy. He is the chairman of radiology at the University of Texas, Southwestern in Houston, and all-around good guy. So welcome, Martin. Martin Pomper: Thank you, Oliver. Very kind of you to say.

Oct 19, 2024 | urotoday.com | Martin G. Pomper

Oliver Sartor interviews Martin Pomper about radiopharmaceuticals and theranostics in cancer treatment. Dr. Pomper discusses his long-standing interest in the field, highlighting the advantages of small molecule radiopharmaceuticals over antibodies and other biological agents. He explains his focus on Astatine-211 as a promising alpha emitter for targeted therapy, citing its single alpha decay and shorter half-life as key benefits.

Dec 11, 2023 | europeanurology.com | Philipp Hartrampf |Steven P. Rowe |Martin G. Pomper |Molecular Imaging

We would like to thank Anand and colleagues for their letter on Prostate-Specific Membrane Antigen-Reporting and Data System (PSMA-RADS) version (v) 2.0 and would like to provide a point-by-point reply. Overall, we agree that further research and refinement of PSMA positron emission tomography reporting are necessary. To read this article in full you will need to make a paymentSubscribe to European UrologyReferencesProstate-Specific Membrane Antigen Reporting and Data System version 2.0.Eur Urol.

Oct 26, 2023 | jnm.snmjournals.org | Sebastian Hoberück |Klaus Zöphel |Martin G. Pomper |Steven Rowe

This year, the tracer principle, a key concept within nuclear medicine, molecular imaging, and radiotheranostics, is marking the centennial anniversary of its discovery (Fig. 1). Although Marie Curie pioneered the concept of using external radiation to diagnose and treat cancer during World War I, the first use of radioactivity to quantify a biologic process was reported by George de Hevesy in May 1923 (1).